⏳ Fetching live dividend data...
Home › Calculator › MRVFF Dividend Calculator 2026
Nuvo Pharmaceuticals Inc. · OTC
Price: $0.98 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in MRVFF → $678.25M in 10 years · $37,939,784.01/month
Nuvo Pharmaceuticals Inc., which operates globally under the trade name Miravo Healthcare, specializes in delivering both prescription and over-the-counter medical products. The company's diverse portfolio addresses key therapeutic areas, including pain management, allergy relief, neurological conditions, and dermatological concerns. Its operations are structured into three distinct business units: a Commercial division, a Production and Service division, and a Licensing and Royalty division. Among its significant offerings are Blexten, an antihistamine prescribed for the symptomatic treatment of allergic rhinitis and chronic spontaneous urticaria; Cambia, a nonsteroidal anti-inflammatory drug for migraine episodes; and Suvexx/Treximet, another medication for migraine. Nuvo also provides NeoVisc, an injectable viscosupplement utilized in managing osteoarthritis, alongside treatments for head lice infestations such as Resultz, FullMarks, and LAUSBUB. For metabolic health, the company supplies Bezalip SR, aimed at patients with elevated cholesterol or triglyceride levels, and Proferrin, an iron supplement for the prevention and treatment of iron deficiency. Their pain relief options include Fiorinal 1 and Fiorinal C1 for tension-type headaches, and Collatamp G, designed for surgical implantation during operations. Nuvo's gastrointestinal product line features PegaLAX, a laxative for occasional constipation; Mutaflor, a probiotic to manage chronic constipation, abdominal pain, and cramps; and MoviPrep, used for bowel cleansing in preparation for colonoscopies. Soriatane is available for the treatment of psoriasis and other keratinization disorders. Additionally, their range of topical solutions includes Pennsaid and Pennsaid 2% for osteoarthritic pain; Vimovo, which alleviates arthritis symptoms; SYNERA and RAPYDAN topical patches, employed to mitigate pain during needle sticks and other superficial skin procedures; and the Heated Lidocaine/Tetracaine Patch, applied prior to painful medical interventions. Yosprala is also part of their portfolio, focused on preventing heart attacks and strokes. The company was originally incorporated in 1983 and was formerly known as Nuvo Research Inc. It officially adopted the name Nuvo Pharmaceuticals Inc. in March 2016 and maintains its corporate headquarters in Mississauga, Canada.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open MRVFF position with:
Real after-tax yield depends on where you live and how you hold MRVFF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 204.19% | 201.39% | $20,419 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 173.56% | 170.76% | $17,356 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 163.35% | 160.55% | $16,335 / yr |
| 🇬🇧 UK ISA | 0% | 204.19% | 201.39% | $20,419 / yr |
| 🇬🇧 UK Taxable | 8.75% | 186.32% | 183.52% | $18,632 / yr |
| 🇨🇦 TFSA | 0% | 204.19% | 201.39% | $20,419 / yr |
| 🇨🇦 CA Taxable | 25% | 153.14% | 150.34% | $15,314 / yr |
| 🇦🇺 Super (pension) | 15% | 173.56% | 170.76% | $17,356 / yr |
| 🇦🇺 AU Taxable | 30% | 142.93% | 140.13% | $14,293 / yr |
| 🇩🇪 DE Taxable | 26.375% | 150.33% | 147.53% | $15,033 / yr |
| 🇫🇷 FR Taxable | 30% | 142.93% | 140.13% | $14,293 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
MRVFF pays quarterly — 4 times per year. Next ex-div: TBD.
How MRVFF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for MRVFF sourced from FMP /financial-growth endpoint — real data, not estimates.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the MRVFF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Nuvo Pharmaceuticals Inc. (MRVFF) is currently trading at $0.98, 16% below its 52-week high. The current dividend yield is 204.19% based on an annual payout of $2.00 per share.
Nuvo Pharmaceuticals Inc. (MRVFF) is a healthcare stock currently trading at $0.98 with a dividend yield of 204.19%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →